PMLRARA AML – M3 APML Test
Test Name: PMLRARA AML – M3 APML Test
Components: Sodium Heparin Vacutainer (2ml)
Price: 1050.0 AED
Sample Condition: Bone Marrow / Peripheral blood
Report Delivery: 3-4 days
Method: FISH
Test type: Genetics
Doctor: Oncology
Test Department:
Pre Test Information: PML/RARA (AML – M3 APML) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
PML/RARA is a specific subtype of acute myeloid leukemia (AML) known as acute promyelocytic leukemia (APML) or AML-M3. It is characterized by the presence of a specific genetic mutation called PML/RARA fusion gene.
In APML, there is an abnormal fusion of two genes, namely PML (promyelocytic leukemia) and RARA (retinoic acid receptor alpha). This fusion gene produces a protein that disrupts the normal maturation of myeloid cells, leading to an accumulation of immature promyelocytes in the bone marrow and blood.
The symptoms of PML/RARA (APML) may include easy bruising, bleeding, fatigue, fever, weight loss, and frequent infections. Patients with this subtype of AML are at a higher risk of bleeding and disseminated intravascular coagulation (DIC) due to the abnormal promyelocytes interfering with the normal clotting process.
Treatment for PML/RARA (APML) typically involves a combination of chemotherapy and a targeted therapy called all-trans retinoic acid (ATRA). ATRA helps to induce differentiation of the immature promyelocytes into mature cells, allowing them to function normally. Chemotherapy is also used to eliminate the leukemic cells. In some cases, stem cell transplantation may be considered as a treatment option.
Overall, PML/RARA (APML) is a subtype of AML characterized by a specific genetic mutation and requires a specific treatment approach involving ATRA and chemotherapy. With appropriate treatment, the prognosis for patients with PML/RARA (APML) has significantly improved over the years.
| Test Name | PMLRARA AML – M3 APML Test |
|---|---|
| Components | Sodium Heparin Vacutainer (2ml) |
| Price | 1050.0 AED |
| Sample Condition | Bone Marrow \/ Peripheral blood |
| Report Delivery | 3-4 days |
| Method | FISH |
| Test type | Genetics |
| Doctor | Oncology |
| Test Department: | |
| Pre Test Information | PML/RARA (AML – M3 APML]) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details | PML/RARA is a specific subtype of acute myeloid leukemia (AML) known as acute promyelocytic leukemia (APML) or AML-M3. It is characterized by the presence of a specific genetic mutation called PML/RARA fusion gene. In APML, there is an abnormal fusion of two genes, namely PML (promyelocytic leukemia) and RARA (retinoic acid receptor alpha). This fusion gene produces a protein that disrupts the normal maturation of myeloid cells, leading to an accumulation of immature promyelocytes in the bone marrow and blood. The symptoms of PML/RARA (APML) may include easy bruising, bleeding, fatigue, fever, weight loss, and frequent infections. Patients with this subtype of AML are at a higher risk of bleeding and disseminated intravascular coagulation (DIC) due to the abnormal promyelocytes interfering with the normal clotting process. Treatment for PML/RARA (APML) typically involves a combination of chemotherapy and a targeted therapy called all-trans retinoic acid (ATRA). ATRA helps to induce differentiation of the immature promyelocytes into mature cells, allowing them to function normally. Chemotherapy is also used to eliminate the leukemic cells. In some cases, stem cell transplantation may be considered as a treatment option. Overall, PML/RARA (APML) is a subtype of AML characterized by a specific genetic mutation and requires a specific treatment approach involving ATRA and chemotherapy. With appropriate treatment, the prognosis for patients with PML/RARA (APML) has significantly improved over the years. |
